Quick Takeaways
- ALPINE IMMUNE SCIENCES, INC. has 21 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
- Info
- Insider Trading
- Financials
Insider Transactions Reported by 21 Insiders of ALPINE IMMUNE SCIENCES, INC.
- Location
- Seattle, WA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 14 Apr 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
ALPINE IMMUNE SCIENCES, INC. executives and other stock owners filed with the SEC include:
Top shareholders of ALPINE IMMUNE SCIENCES, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
6,582,380
|
$83,859,521 | — | 18 Jan 2024 | |
| Jay R. Venkatesan |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
2,946,372
mixed-class rows
|
$36,644,978 | — | 15 Jul 2022 | |
| Alpine ImmunoSciences, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,600,980
|
$33,136,485 | — | 17 Sep 2021 | |
| Decheng Capital Global Healthcare Fund (Master), LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,735,544
|
$22,110,831 | — | 09 Nov 2023 | |
| Frazier Life Sciences VIII, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,484,115
|
$18,907,625 | — | 11 Feb 2022 | |
| Wolfgang Dummer |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
200,000
|
— | — | 02 Oct 2023 | |
| Zelanna Goldberg |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
160,000
|
— | — | 01 Jun 2021 | |
| Andrew Seth Sandler |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
50,000
|
— | — | 05 Jan 2023 |
Recent Insider Transactions by Companies or Individuals for ALPINE IMMUNE SCIENCES, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.